Skip to main content

Table 5 Patients’ distribution among severity grades of GI manifestations determined at Day-3 and Day-6 compared to Day-0 distribution in both groups

From: Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study

Symptom

Time

Control

Study

P value

Nil

Mild

Moderate

Severe

Nil

Mild

Moderate

Severe

Nausea

Day-0

6

7

6

5

5

8

7

4

>0.05

Day-3

12

8

4

0

19

4

1

0

>0.05

Day-6

22

2

0

0

24

0

0

0

0.047

Day-8

24

0

0

0

24

0

0

0

>0.05

Vomiting

Day-0

12

8

4

0

14

7

2

1

>0.05

Day-3

20

4

0

0

24

0

0

0

0.037

Day-6

24

0

0

0

24

0

0

0

>0.05

Day-8

24

0

0

0

24

0

0

0

>0.05

Abdominal distension

Day-0

4

7

10

3

5

8

9

2

>0.05

Day-3

9

12

3

0

15

8

1

0

>0.05

Day-6

20

4

0

0

24

0

0

0

0.037

Day-8

24

0

0

0

24

0

0

0

>0.05